X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
imatinib-resistant (320) 320
humans (253) 253
index medicus (246) 246
chronic myelogenous leukemia (178) 178
dasatinib (178) 178
oncology (168) 168
chronic myeloid-leukemia (165) 165
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (153) 153
chronic myeloid leukemia (142) 142
hematology (127) 127
bcr-abl (122) 122
cytogenetic responses (107) 107
male (104) 104
protein kinase inhibitors - therapeutic use (97) 97
nilotinib (95) 95
female (94) 94
adult (87) 87
middle aged (87) 87
pyrimidines - therapeutic use (85) 85
aged (75) 75
antineoplastic agents - therapeutic use (72) 72
chronic-phase (72) 72
tyrosine kinase inhibitor (72) 72
imatinib mesylate (71) 71
leukemia (69) 69
cancer (65) 65
hemic and lymphatic diseases (63) 63
follow-up (58) 58
treatment outcome (57) 57
benzamides (56) 56
protein-tyrosine kinases - antagonists & inhibitors (55) 55
cml (54) 54
pharmacology & pharmacy (53) 53
pyrimidines - adverse effects (53) 53
therapy (52) 52
pyrimidines - pharmacology (50) 50
tyrosine kinase inhibitors (50) 50
leukemia, myelogenous, chronic, bcr-abl positive - genetics (49) 49
care and treatment (48) 48
pyrimidines - administration & dosage (48) 48
imatinib (46) 46
acute lymphoblastic-leukemia (45) 45
mutation (44) 44
research (44) 44
fusion proteins, bcr-abl - genetics (43) 43
tyrosine (43) 43
protein kinase inhibitors - pharmacology (42) 42
thiazoles - therapeutic use (42) 42
leukemia, myelogenous, chronic, bcr-abl positive - pathology (41) 41
drug therapy (39) 39
piperazines - therapeutic use (39) 39
philadelphia-chromosome (38) 38
thiazoles - adverse effects (38) 38
tyrosine kinase (37) 37
drug resistance, neoplasm (36) 36
fusion proteins, bcr-abl - antagonists & inhibitors (36) 36
protein kinase inhibitors - adverse effects (36) 36
blast crisis (34) 34
protein kinase inhibitors - administration & dosage (34) 34
antineoplastic agents - pharmacology (33) 33
medicine & public health (33) 33
thiazoles - administration & dosage (32) 32
animals (31) 31
bms-354825 (31) 31
efficacy (31) 31
genetic aspects (31) 31
young adult (31) 31
in-vitro (30) 30
intolerant (29) 29
adolescent (28) 28
antineoplastic agents (28) 28
antineoplastic agents - administration & dosage (28) 28
kinases (28) 28
piperazines - pharmacology (28) 28
abridged index medicus (27) 27
aged, 80 and over (27) 27
antimitotic agents (27) 27
antineoplastic agents - adverse effects (26) 26
dosage and administration (26) 26
drug resistance (26) 26
drug resistance, neoplasm - genetics (25) 25
fusion proteins, bcr-abl - metabolism (25) 25
accelerated-phase (24) 24
analysis (24) 24
apoptosis (24) 24
apoptosis - drug effects (24) 24
health aspects (24) 24
article (23) 23
failure (23) 23
hematology, oncology and palliative medicine (23) 23
interferon-alpha (23) 23
risk factors (23) 23
accelerated phase (22) 22
clinical trials as topic (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (22) 22
cancer research (21) 21
chemotherapy (21) 21
complications and side effects (21) 21
drug administration schedule (21) 21
thiazoles - pharmacology (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 2013, Volume 40, Issue 13, pp. 2573 - 2575
Journal Article
Haematologica, ISSN 0390-6078, 01/2019, Volume 104, Issue 1, pp. 93 - 101
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia... 
CYTOGENETIC RESPONSES | IMATINIB-RESISTANT | INTOLERANT CHRONIC-PHASE | INHIBITION | EFFICACY | TOLERABILITY | FOLLOW-UP | HEMATOLOGY | FAILURE | CHRONIC MYELOID-LEUKEMIA
Journal Article
DRUGS, ISSN 0012-6667, 01/2017, Volume 77, Issue 1, pp. 85 - 96
Dasatinib (Sprycel (R)) is an orally administered, small molecule inhibitor of multiple tyrosine kinases. In the phase 3 DASISION trial, dasatinib 100 mg once... 
LARGE GRANULAR LYMPHOCYTOSIS | TYROSINE KINASE INHIBITORS | CYTOGENETIC RESPONSES | ACCELERATED PHASE | 100 MG | IMATINIB-RESISTANT | INTOLERANT CHRONIC-PHASE | EUROPEAN LEUKEMIANET | BCR-ABL | PHARMACOLOGY & PHARMACY | TOXICOLOGY | 2-YEAR FOLLOW-UP
Journal Article
BLOOD, ISSN 0006-4971, 03/2012, Volume 119, Issue 10, pp. 2234 - 2238
Specific imatinib-resistant BCR-ABL1 mutations (Y253H, E255K/V, T315I, F317L, and F359V/C) predict failure of second-line nilotinib or dasatinib therapy in... 
IMATINIB-RESISTANT | REPAIR | CLONAL DIVERSITY | THERAPY | ACCELERATED-PHASE | BCR-ABL MUTATIONS | DOMAIN MUTATIONS | DASATINIB | HEMATOLOGY | NILOTINIB | PROGRESSION
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2019, Volume 105, Issue 2, pp. 363 - 375
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have... 
CELL LUNG-CANCER | INTRINSIC RESISTANCE | IMATINIB-RESISTANT | BIM DELETION POLYMORPHISM | OBINUTUZUMAB GA101 | PHARMACOLOGY & PHARMACY | PHASE-I SAFETY | OPEN-LABEL | MONOCLONAL-ANTIBODIES | METABOLIZING-ENZYMES | CHRONIC MYELOID-LEUKEMIA
Journal Article
Blood, ISSN 0006-4971, 12/2011, Volume 118, Issue 25, pp. 6521 - 6528
Journal Article
Journal Article
Journal Article
REVUE DES MALADIES RESPIRATOIRES, ISSN 0761-8425, 01/2015, Volume 32, Issue 1, pp. 84 - 86
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 07/2018, Volume 124, Issue 13, pp. 2687 - 2689
A lower dose of 50 mg of dasatinib is effective when used as the initial treatment of patients with chronic‐phase chronic myeloid leukemia. This observation... 
TRIAL | IMATINIB-RESISTANT | CML | CHRONIC-PHASE | ONCOLOGY | CHRONIC MYELOID-LEUKEMIA | Antineoplastic Agents | Dasatinib | Leukemia, Myeloid, Chronic-Phase | Humans | Antitumor agents | Chronic myeloid leukemia | Myeloid leukemia | Leukemia | Cancer
Journal Article